| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 341 | 2020 |
| De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans T Deuse, X Hu, S Agbor-Enoh, M Koch, MH Spitzer, A Gravina, M Alawi, ... Nature Biotechnology 37 (10), 1137-1144, 2019 | 89 | 2019 |
| TCRMatch: predicting T-cell receptor specificity based on sequence similarity to previously characterized receptors WD Chronister, A Crinklaw, S Mahajan, R Vita, Z Koşaloğlu-Yalçın, Z Yan, ... Frontiers in immunology 12, 640725, 2021 | 85 | 2021 |
| Predicting T cell recognition of MHC class I restricted neoepitopes Z Koşaloğlu-Yalçın, M Lanka, A Frentzen, ... Oncoimmunology 7 (11), e1492508, 2018 | 85 | 2018 |
| CCR5 status and metastatic progression in colorectal cancer M Suarez-Carmona, P Chaorentong, JN Kather, R Rothenheber, ... Oncoimmunology 8 (9), e1626193, 2019 | 38 | 2019 |
| Targeting fibroblast growth factor receptor 1 for treatment of soft-tissue sarcoma P Chudasama, M Renner, M Straub, SS Mughal, B Hutter, Z Kosaloglu, ... Clinical cancer research 23 (4), 962-973, 2017 | 38 | 2017 |
| Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial J Michels, N Becker, S Suciu, I Kaiser, A Benner, Z Kosaloglu-Yalcin, ... Oncoimmunology 7 (6), e1428157, 2018 | 25 | 2018 |
| The cancer epitope database and analysis resource (CEDAR) Z Koşaloğlu-Yalçın, N Blazeska, R Vita, H Carter, M Nielsen, ... Nucleic acids research 51 (D1), D845-D852, 2023 | 18 | 2023 |
| In silico SNP analysis of the breast cancer antigen NY-BR-1 Z Kosaloglu, J Bitzer, N Halama, Z Huang, M Zapatka, A Schneeweiss, ... BMC cancer 16, 1-12, 2016 | 17 | 2016 |
| Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases Z Koşaloğlu, I Zörnig, N Halama, I Kaiser, I Buchhalter, N Grabe, R Eils, ... Oncoimmunology 5 (11), e1213931, 2016 | 17 | 2016 |
| Impact of cysteine residues on MHC binding predictions and recognition by tumor-reactive T cells A Sachs, E Moore, Z Kosaloglu-Yalcin, B Peters, J Sidney, SA Rosenberg, ... The Journal of Immunology 205 (2), 539-549, 2020 | 15 | 2020 |
| Mismatch repair deficiency drives durable complete remission by targeting programmed death receptor 1 in a metastatic luminal breast cancer patient C Fremd, M Hlevnjak, M Zapatka, I Zoernig, N Halama, N Fejzibegovic, ... Breast Care 14 (1), 53-59, 2019 | 12 | 2019 |
| Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions Z Koşaloğlu-Yalçın, J Lee, J Greenbaum, SP Schoenberger, A Miller, ... IScience 25 (2), 2022 | 11 | 2022 |
| The cancer epitope database and analysis resource: a blueprint for the establishment of a new bioinformatics resource for use by the cancer immunology community Z Koşaloğlu-Yalçın, N Blazeska, H Carter, M Nielsen, E Cohen, D Kufe, ... Frontiers in Immunology 12, 735609, 2021 | 11 | 2021 |
| In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden V Ferrari, A Tarke, H Fields, L Ferrari, T Conley, F Ferrari, ... Cytotherapy 23 (4), 320-328, 2021 | 9 | 2021 |
| Predicting the success of fmoc-based peptide synthesis I Gutman, R Gutman, J Sidney, L Chihab, M Mishto, J Liepe, A Chiem, ... ACS omega 7 (27), 23771-23781, 2022 | 8 | 2022 |
| Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLA‐DQ2. 5 Z Koşaloğlu‐Yalçın, J Sidney, W Chronister, B Peters, A Sette Immunology 162 (2), 235-247, 2021 | 8 | 2021 |
| The role of antigen expression in shaping the repertoire of HLA presented ligands HMG Alvarez, Z Koşaloğlu-Yalçın, B Peters, M Nielsen Iscience 25 (9), 2022 | 6 | 2022 |
| Allele-specific thresholds of eluted ligands for T-cell epitope prediction B Reardon, Z Koşaloğlu-Yalçın, S Paul, B Peters, A Sette Molecular & Cellular Proteomics 20, 2021 | 6 | 2021 |
| A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer. A Miller, Z Kosaloglu-Yalcin, L Westernberg, L Montero, M Bahmanof, ... Journal of Clinical Oncology 39 (15_suppl), 2615-2615, 2021 | 4 | 2021 |
Stefan B. EichmüllerGerman Cancer Research Center (DKFZ)Verified email at dkfz.de
